Kallikrein 6 antibody (AA 217-244) (Biotin)
Quick Overview for Kallikrein 6 antibody (AA 217-244) (Biotin) (ABIN759103)
Target
See all Kallikrein 6 (KLK6) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 217-244
-
Cross-Reactivity
- Rat
-
Predicted Reactivity
- Human,Mouse
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human KLK6
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C for 12 months.
-
Expiry Date
- 12 months
-
-
- Kallikrein 6 (KLK6)
-
Alternative Name
- Klk6
-
Background
-
Synonyms: hK6, Bssp, Klk7, SP59, PRSS9, PRSS18, Kallikrein-6, Neurosin, Protease M, Serine protease 18, Serine protease 9, Zyme, KLK6
Background: Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis.
-
Gene ID
- 5653
-
UniProt
- Q92876
-
Pathways
- Complement System, Regulation of G-Protein Coupled Receptor Protein Signaling
Target
-